

DOCON TECHNOLOGIES PRIVATE LIMITED

August 13, 2026

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051	To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001
To, Thyrocare Technologies Limited D37/3, TTC MIDC, Turbhe, Navi Mumbai – 400 073	

Sub: Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 – Sale of 1,57,69,696 Equity Shares of Thyrocare Technologies Limited by Promoter

We hereby inform you that **Docon Technologies Private Limited** (“Docon”), a wholly owned subsidiary of **API Holdings Limited** (“API”) and a Promoter & Holding Company of **Thyrocare Technologies Limited** (“Thyrocare”), which was holding **60.92%** of the total equity share capital of Thyrocare, has sold **1,57,69,696 equity shares**, representing approximately 9.9% of the total paid-up share capital of Thyrocare.

Pursuant to the requirements of **Regulation 29(2)** of the *Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011*, we enclose herewith the necessary disclosure in the prescribed format as **Annexure I**.

Following the aforesaid transaction, Docon continues to remain the Promoter & Holding Company of the Thyrocare. Post this aforesaid sale, the promoter shareholding in Thyrocare has been reduced from **60.92%** to **51.02%** of the total paid-up equity share capital.

You are requested to take the same on record.

For **Docon Technologies Private Limited**


Madhuri Sudhir Sarangdhar
Company Secretary



DOCON TECHNOLOGIES PRIVATE LIMITED

Annexure I

Disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Thyrocare Technologies Limited ("Thyrocare")		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: #Docon Technologies Private Limited (The Acquirer has not acquired any additional shares. This disclosure is being made solely to inform stakeholders about the disposal of shares related to Thyrocare Technologies Limited)		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. National Stock Exchange of India Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share /voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a. Shares carrying voting rights	1,75,00,000	10.99	10.96
b. Shares in the nature of encumbrance (pledge /lien/ non-disposal undertaking/ others)	7,94,69,696	49.93	49.79
c. Voting rights (VR) otherwise than by shares	NIL	NIL	NIL
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	NIL	NIL	NIL
e. Total (a+b+c+d)	9,69,69,696	60.92	60.75
Details of acquisition/sale			
a. Shares carrying voting rights acquired/sold	1,57,69,696	9.90	9.88
b. VRs acquired /sold otherwise than by shares	NIL	NIL	NIL
c. Warrants/convertible securities/any other	NIL	NIL	NIL

DOCON TECHNOLOGIES PRIVATE LIMITED

d. instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold Shares encumbered / invoked/released by the acquirer)	NIL	NIL	NIL
e. Total (a+b+c+/-d)	1,57,69,696	9.90	9.88
After the acquisition/sale, holding of:			
a. Shares carrying voting rights	17,30,304	1.09	1.08
b. *Shares encumbered with the acquirer	7,94,69,696	49.93	49.79
c. VRs otherwise than by shares	NIL	NIL	NIL
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	NIL	NIL	NIL
e. Total (a+b+c+d)	8,12,00,000	51.02	50.87
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Sale of 1,57,69,696 equity shares of Thyrocare Technologies Limited on market trades (including block deals)		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	August 13, 2026.		
Equity share capital / total voting capital of the TC before the said acquisition / sale	15,91,65,315 Equity shares having face value of Rs. 10 each		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	15,91,65,315 Equity shares having face value of Rs. 10 each		
Total diluted share/voting capital of the TC after the said acquisition	15,96,30,252 equity shares having face value of Rs. 10 each		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

The Acquirer has not acquired any additional shares. This disclosure is being made solely to inform stakeholders about the disposal of shares related to Thyrocare Technologies Limited.

For and on behalf of **Docon Technologies Private Limited**

Madhuri Sudhir Sarangdhar

Company Secretary

Date: August 13, 2026

